The Survivors of Nothingness — Part Two    EGAS, Eni, TotalEnergies sign Cronos field handling agreement    Oil prices drop on Tuesday    Asian stocks climb on Tuesday    SCZONE attracts $65m in new Chinese textile investments in Sokhna Industrial Zone    Egypt, Boeing discuss expanding aviation partnership, investment cooperation    Egypt, Eroğlu Group discuss textile investment, partnership opportunities    Egypt discusses troop deployment to Somalia with foreign minister    Israel accused of 80 ceasefire violations in Gaza since October 10    Egypt's PM reviews efforts to remove Nile River encroachments    Health Minister reviews readiness of Minya for rollout of universal health insurance    Egypt strengthens ties with NEPAD at Aswan Forum    Sisi invites Egyptians to join Gaza reconstruction drive, citing shared humanity    Egypt screens 13.3m under presidential cancer detection initiative since mid-2023    Egypt launches official website for Grand Egyptian Museum ahead of November opening    The Survivors of Nothingness — Episode (I)    EHA, Arab Hospitals Federation discuss cooperation on AI, sustainable healthcare    Al-Sisi: Cairo to host Gaza reconstruction conference in November    Egypt, WHO sign cooperation strategy to strengthen health system through 2028    Egypt's FM joins Sahel region roundtable at Aswan Forum    Egypt successfully hosts Egyptian Amateur Open golf championship with 19-nation turnout    Africa can lead global recovery, Egypt's Sisi tells Aswan Forum    Egypt: Guardian of Heritage, Waiting for the World's Conscience    Egypt, Qatar sign MoU to boost cooperation in healthcare, food safety    Egypt will never relinquish historical Nile water rights, PM says    Al Ismaelia launches award-winning 'TamaraHaus' in Downtown Cairo revival    Al-Sisi, Burhan discuss efforts to end Sudan war, address Nile Dam dispute in Cairo talks    Egypt's Sisi warns against unilateral Nile actions, calls for global water cooperation    Egypt unearths New Kingdom military fortress on Horus's Way in Sinai    Egyptian Open Amateur Golf Championship 2025 to see record participation    Syria releases preliminary results of first post-Assad parliament vote    Karnak's hidden origins: Study reveals Egypt's great temple rose from ancient Nile island    Egypt resolves dispute between top African sports bodies ahead of 2027 African Games    Egypt aims to reclaim global golf standing with new major tournaments: Omar Hisham    Germany among EU's priciest labour markets – official data    Paris Olympic gold '24 medals hit record value    It's a bit frustrating to draw at home: Real Madrid keeper after Villarreal game    Russia says it's in sync with US, China, Pakistan on Taliban    Shoukry reviews with Guterres Egypt's efforts to achieve SDGs, promote human rights    Sudan says countries must cooperate on vaccines    Johnson & Johnson: Second shot boosts antibodies and protection against COVID-19    Egypt to tax bloggers, YouTubers    Egypt's FM asserts importance of stability in Libya, holding elections as scheduled    We mustn't lose touch: Muller after Bayern win in Bundesliga    Egypt records 36 new deaths from Covid-19, highest since mid June    Egypt sells $3 bln US-dollar dominated eurobonds    Gamal Hanafy's ceramic exhibition at Gezira Arts Centre is a must go    Italian Institute Director Davide Scalmani presents activities of the Cairo Institute for ITALIANA.IT platform    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



Hope in the fight against Covid-19
Published in Ahram Online on 14 - 04 - 2020

On 7 April, Japanese top diplomat Toshimitsu Motegi declared that his country would allow 20 other countries to test Avigan, a drug for influenza that has helped patients in China to recover from the Covid-19 coronavirus.
Its usefulness has yet to be confirmed in clinical tests, but Japan seeks to “work with interested countries to expand clinical research on Avigan internationally,” Motegi said, in order to find out whether it could be effective as a therapy against the coronavirus.
Among the countries involved in the Avigan tests are Bulgaria, the Czech Republic, Indonesia, Iran, Myanmar, Saudi Arabia and Turkey. Thirty more countries, according to Motegi, are also interested in trying it.
The Japanese Fujifilm Corporation, Avigan's producer, issued a statement saying that about 50 coronavirus patients in the United States would be given the drug as part of a joint project between the company and Brigham and Women's Hospital in Boston, Massachusetts General Hospital and the University of Massachusetts Medical School.
Egypt has also expressed interest in the drug. “We are on our way to the manufacturing stage... after we contact the Chinese side responsible for producing the pharmaceutical ingredients ... and the approval of the Japanese company… to get enough of the ingredients in order to manufacture the drug,” Higher Education and Scientific Research Minister Khaled Abdel-Ghaffar said last week.
Avigan earned approval for manufacture in Japan in 2014 as an antiviral influenza drug. Fujifilm said that it is to “be considered for use only when there is an outbreak of novel or re-emerging influenza virus infections in which other influenza antiviral drugs are either not effective or insufficiently effective. The Japanese government has decided to use the drug as a countermeasure against such influenza viruses.”
The company said that Avigan was a promising therapy for the novel coronavirus because it “has a mechanism of action for selectively inhibiting RNA polymerase involved in influenza viral replication.” Covid-19 “is classified in the same type of single-stranded RNA virus as influenza, and its [Avigan's] clinical application to treat Covid-19 is now under study,” Fujifilm said in a press statement on 31 March.
In March, the Chinese medical authorities praised Avigan for having “a high degree of safety and [being] clearly effective in the treatment” of coronavirus. It had been used on 340 patients in Wuhan and Shenzan, and patients who had tested positive for coronavirus recovered almost four days after taking the drug, they said.
Those who did not, according to Japan's NHK national broadcaster, felt better after roughly 11 days. A source at the Japanese Health Ministry told the Mainichi Shimbun, a Japanese newspaper, that Avigan “doesn't seem to work that well when the virus has already multiplied,” suggesting that the drug should be used early in the infection.
Medical researchers, pharmaceutical companies and world leaders have repeatedly emphasised that a vaccine for coronavirus will not be ready before a year from now. A reliable therapy is thus greatly needed.
According to World Health Organisation (WHO) figures, more than two million people around the world tested positive for coronavirus.
*A version of this article appears in print in the 16 April, 2020 edition of Al-Ahram Weekly


Clic here to read the story from its source.